Juno Therapeutics Inc (NASDAQ:JUNO) had its price target lowered by research analysts at Maxim Group from $50.00 to $34.00 in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price points to a potential upside of 13.79% from the company’s current price.

JUNO has been the subject of a number of other reports. FBR & Co set a $61.00 price target on Juno Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 5th. Vetr downgraded Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 price target for the company. in a research report on Tuesday, August 16th. Standpoint Research initiated coverage on Juno Therapeutics in a research report on Thursday, August 25th. They issued a “buy” rating and a $47.00 price target for the company. BTIG Research initiated coverage on Juno Therapeutics in a research report on Tuesday, August 30th. They issued a “sell” rating and a $23.00 price target for the company. Finally, Zacks Investment Research upgraded Juno Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Five analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $43.13.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ:JUNO) traded down 27.21% during midday trading on Wednesday, reaching $21.75. 14,537,509 shares of the company were exchanged. The company has a 50-day moving average of $27.93 and a 200 day moving average of $33.09. The firm’s market capitalization is $2.23 billion. Juno Therapeutics has a 52 week low of $19.41 and a 52 week high of $57.82.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.05. The company had revenue of $20.80 million for the quarter, compared to analysts’ expectations of $10.98 million. During the same period in the previous year, the business posted ($0.26) earnings per share. The business’s quarterly revenue was up 1200.0% compared to the same quarter last year. Equities analysts predict that Juno Therapeutics will post ($2.54) earnings per share for the current year.

In other Juno Therapeutics news, CEO Hans Edgar Bishop sold 84,035 shares of Juno Therapeutics stock in a transaction dated Wednesday, September 21st. The stock was sold at an average price of $30.28, for a total value of $2,544,579.80. Following the transaction, the chief executive officer now owns 2,518,537 shares in the company, valued at $76,261,300.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Robert Azelby sold 12,921 shares of Juno Therapeutics stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $24.14, for a total value of $311,912.94. Following the completion of the transaction, the executive vice president now owns 48,640 shares in the company, valued at approximately $1,174,169.60. The disclosure for this sale can be found here.

A number of institutional investors have recently bought and sold shares of JUNO. Rockefeller Financial Services Inc. raised its stake in shares of Juno Therapeutics by 1,433.2% in the third quarter. Rockefeller Financial Services Inc. now owns 3,465 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 3,239 shares during the last quarter. Advisor Group Inc. raised its stake in shares of Juno Therapeutics by 51.4% in the third quarter. Advisor Group Inc. now owns 3,815 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 1,296 shares during the last quarter. Panagora Asset Management Inc. raised its stake in shares of Juno Therapeutics by 55.0% in the third quarter. Panagora Asset Management Inc. now owns 4,200 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 1,490 shares during the last quarter. Societe Generale acquired a new stake in shares of Juno Therapeutics during the second quarter worth $153,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Juno Therapeutics during the second quarter worth $153,000.

COPYRIGHT VIOLATION NOTICE: “Maxim Group Trims Juno Therapeutics Inc (JUNO) Target Price to $34.00” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/23/maxim-group-trims-juno-therapeutics-inc-juno-target-price-to-34-00.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

5 Day Chart for NASDAQ:JUNO

Receive News & Stock Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related stocks with our FREE daily email newsletter.